Exagen Diagnostics

Ticker

XGN

Website

Sector

Healthcare

Tearsheet

Why Invest

AVISE testing portfolio, specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. Large underserved autoimmune disease market with a $5 Billion TAM on current commercial products. Consistent sustainable revenue growth since our IPO in 2019. Robust pipeline focused on large TAM areas that will benefit patients, physicians and payors.

  

  1. Large underserved autoimmune disease market with a $5 Billion TAM on current commercial products.